The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Skyrizi
risankizumab-rzaa · RISANKIZUMAB 180 mg/1.2mL · Injection · Subcutaneous · AbbVie Inc.
NDC 00074-8300-01 · 1 SYRINGE in 1 CARTON / 1.2 mL in 1 SYRINGE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for risankizumab-rzaa (injectable) in the next 90 days
sterile injectable · price up 6% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $20,459.66 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761105
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of risankizumab-rzaa (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| AbbVie Inc. | RISANKIZUMAB 150 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| AbbVie Inc. | RISANKIZUMAB 600 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| AbbVie Inc. | RISANKIZUMAB 180 mg/1.2mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Skyrizi — NDC 00074-8300-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00074830001.
Free to cite with attribution — see how the data is put together.